Anabolic agents work differently from other osteoporosis medications in that they don't just slow down bone loss — they can trigger the growth of new bone.

Injection site reactions, mostly mild in severity, were reported in 5.2 percent of patients in the romosozumab treatment group and 2.9 percent in the placebo group during the 12-month period.

Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial. The findings were ...

Among patients with severe postmenopausal osteoporosis unresponsive to long-term denosumab, addition of romosozumab improved lumbar spine bone mineral density. Denosumab combined with romosozumab may ...

In postmenopausal women with osteoporosis, prior fracture, and type 2 diabetes, 12 months of romosozumab significantly improved bone strength when combined with alendronate, compared with alendronate ...

Romosozumab is a US Food and Drug Administration-approved humanized monoclonal antibody used to treat osteoporosis in postmenopausal women with a high risk for fracture. The study included 70 adults ...

Romosozumab was not associated with increased cardiovascular risks among patients with osteoporosis when compared with bisphosphonate use. Romosozumab does not appear to significantly increase the ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD among postmenopausal women with T2D and osteoporosis. Romosozumab followed by alendronate treatment ...

SEATTLE -- The monoclonal antibody romosozumab (Evenity) increased bone mineral density (BMD) in premenopausal women with idiopathic osteoporosis, according to a small, phase II open-label study.

Osteoporosis treatment requires a “long-game strategy” that involves advance planning and sometimes challenging decision-making about sequential therapy, Gina Woods, MD, osteoporosis clinic director ...